| 000 | 01488 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250516064325.0 | ||
| 264 | 0 | _c20120105 | |
| 008 | 201201s 0 0 ger d | ||
| 022 | _a1439-4413 | ||
| 024 | 7 |
_a10.1055/s-0031-1292063 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aScharf, R E | |
| 245 | 0 | 0 |
_a[Cancer, thromboembolia and antithrombotic therapy: is there an anticoagulant of choice?]. _h[electronic resource] |
| 260 |
_bDeutsche medizinische Wochenschrift (1946) _cNov 2011 |
||
| 300 |
_a2403 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Review | ||
| 650 | 0 | 4 |
_aAnticoagulants _xadverse effects |
| 650 | 0 | 4 |
_aHeparin _xadministration & dosage |
| 650 | 0 | 4 |
_aHeparin, Low-Molecular-Weight _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 | _aLong-Term Care |
| 650 | 0 | 4 |
_aNeoplasms _xcomplications |
| 650 | 0 | 4 | _aPatient Acceptance of Health Care |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aSecondary Prevention |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aThrombin _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aVenous Thromboembolism _xdrug therapy |
| 650 | 0 | 4 |
_aVitamin K _xantagonists & inhibitors |
| 773 | 0 |
_tDeutsche medizinische Wochenschrift (1946) _gvol. 136 _gno. 47 _gp. 2403 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1055/s-0031-1292063 _zAvailable from publisher's website |
| 999 |
_c21322457 _d21322457 |
||